More about

Dapagliflozin

News
May 11, 2020
1 min read
Save

FDA OKs dapagliflozin for heart failure regardless of diabetes status, plus more top stories in cardiology

The FDA has approved the SGLT2 inhibitor dapagliflozin for patients with heart failure with reduced injection fraction regardless of diabetes status. It was the top story in cardiology last week.

News
May 06, 2020
5 min read
Save

FDA approves dapagliflozin for HFrEF regardless of diabetes status

FDA approves dapagliflozin for HFrEF regardless of diabetes status

AstraZeneca announced the FDA has approved its SGLT2 inhibitor dapagliflozin to reduce risk for CV death and HF hospitalization in patients with HF with reduced ejection fraction with and without type 2 diabetes.

News
May 06, 2020
5 min read
Save

FDA approves dapagliflozin for HFrEF regardless of diabetes status

FDA approves dapagliflozin for HFrEF regardless of diabetes status

AstraZeneca announced the FDA has approved its SGLT2 inhibitor dapagliflozin to reduce risk for CV death and HF hospitalization in patients with HF with reduced ejection fraction with and without type 2 diabetes.

News
April 29, 2020
2 min read
Save

Top stories in endocrinology: Trial tests dapagliflozin as COVID-19 treatment, recommended diabetes agents in presence of coronavirus

Top stories in endocrinology: Trial tests dapagliflozin as COVID-19 treatment, recommended diabetes agents in presence of coronavirus

A global phase 3 trial is underway to assess the potential of dapagliflozin as a treatment to reduce COVID-19 progression among adults with cardiovascular, metabolic or renal risk factors. It was the top story last week in endocrinology.

News
April 23, 2020
2 min read
Save

Clinical trial investigates dapagliflozin for COVID-19 treatment

Clinical trial investigates dapagliflozin for COVID-19 treatment

Recruitment for a global phase 3 trial is now underway to assess the potential of the SGLT2 inhibitor dapagliflozin as a treatment to reduce COVID-19 progression, complications and death among adults with cardiovascular, metabolic or renal risk factors, according to a press release from AstraZeneca and St. Luke’s Mid America Heart Institute.

News
March 30, 2020
1 min read
Save

DAPA-CKD trial stopped early after ‘overwhelming benefit’ observed with dapagliflozin

DAPA-CKD trial stopped early after ‘overwhelming benefit’ observed with dapagliflozin

The phase 3 DAPA-CKD trial assessing the benefit of the SGLT2 inhibitor dapagliflozin in adults with chronic kidney disease will be stopped early after investigators reported an “overwhelming benefit” for reduction in worsening renal function or renal death compared with placebo, according to a press release from AstraZeneca.

News
February 17, 2020
1 min read
Save

Top stories in cardiology: Dapagliflozin reduces AF in high-risk patients, physical inactivity confers similar health risks to smoking

Top stories in cardiology: Dapagliflozin reduces AF in high-risk patients, physical inactivity confers similar health risks to smoking

Researchers found that high-risk patients with diabetes who were treated with dapagliflozin experienced a decrease in atrial fibrillation and atrial flutter incidences. It was the week’s top story in cardiology.

News
February 15, 2020
4 min read
Save

Novel once-daily pill reduces HbA1c in type 1 diabetes

Novel once-daily pill reduces HbA1c in type 1 diabetes

An investigational, once-daily pill added to optimized insulin therapy was shown to reduce HbA1c among adults with type 1 diabetes during a 12-week trial when compared with placebo plus insulin, according to a press release from vTv Therapeutics.

News
February 11, 2020
2 min read
Save

Dapagliflozin reduces AF events in high-risk patients with diabetes

Dapagliflozin reduces AF events in high-risk patients with diabetes

High-risk patients with diabetes who were treated with dapagliflozin had a decrease in the incidence of atrial fibrillation and atrial flutter, according to an analysis of the DECLARE-TIMI 58 trial published in Circulation.

News
January 17, 2020
3 min read
Save

Dapagliflozin may improve lung fluid volume in HF

Dapagliflozin may improve lung fluid volume in HF

PHILADELPHIA — Treatment with the SGLT2 inhibitor dapagliflozin was not associated with a reduction in mean lung fluid volume among adults with HF with reduced ejection fraction compared with placebo.

View more